+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Nuclear Medicine Market Report and Forecast 2023-2031

  • PDF Icon


  • 140 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855099
The nuclear medicine market size was valued at USD 8.19 billion in 2022, driven by the rise in the geriatric population across the globe. The market is anticipated to grow at a CAGR of 11.72% during the forecast period of 2023-2031 to achieve a value of USD 22.26 billion by 2031.

Nuclear Medicine: Introduction

Nuclear medicine is a medical specialty that utilizes radioactive materials called radiopharmaceuticals to diagnose and treat various diseases. It involves the use of gamma cameras, PET scanners, and other imaging devices to capture images of the body's organs, tissues, and metabolic processes at the molecular level.

The use of nuclear medicine has significantly advanced medical diagnostics and treatment. It offers a non-invasive and highly sensitive approach to detect diseases, assess their severity, and monitor the effectiveness of treatments. Nuclear medicine techniques, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging systems like PET/CT and SPECT/CT, have revolutionized medical imaging by providing anatomical and functional information in a single examination.

Key Trends in the Nuclear Medicine Market

Some key trends involved in the nuclear medicine market are as follows:
  • Increasing Applications: Nuclear medicine is finding applications in various medical fields, including cardiology, oncology, neurology, and orthopedics. The ability to detect diseases at an early stage and monitor treatment response has contributed to the expanding use of nuclear medicine techniques
  • Technological Advancements: The field of nuclear medicine has witnessed significant technological advancements in recent years. Improved imaging systems, such as hybrid PET/CT and SPECT/CT scanners, provide precise anatomical and functional information, enhancing the accuracy of diagnoses and treatment planning
  • Theranostics: Theranostics is a rapidly evolving field within nuclear medicine that combines diagnostic imaging and targeted therapy. It involves the use of radiopharmaceuticals that can both diagnose and treat diseases, such as certain types of cancer. Theranostics offers personalized medicine approaches and has shown promising results in improving patient outcomes
  • Radiopharmaceutical Developments: Ongoing research and development efforts are focused on developing new radiopharmaceuticals with improved diagnostic capabilities and therapeutic efficacy. This includes the development of novel tracers for specific diseases and the utilization of theranostic agents for targeted therapies

Nuclear Medicine Market Segmentations

Market Breakup by Type

Diagnostic Nuclear Medicine

  • SPECT (Single-Photon Emission Computed Tomography)
  • PET (Positron Emission Tomography) Radiopharmaceuticals

Therapeutic Nuclear Medicine

  • Beta Emitters
  • Alpha Emitters
  • Brachytherapy Isotopes

Market Breakup by Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

Market Breakup by End User

  • Hospitals and Clinics
  • Diagnostic Centres
  • Academic Research Institutions
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Nuclear Medicine Market Scenario

The global market for nuclear medicine, also known as molecular imaging, is witnessing significant growth. Nuclear medicine techniques have revolutionized the field of medical imaging by providing unique insights into the functioning of organs and tissues at a molecular level. This advanced imaging technology involves the use of radiopharmaceuticals that emit gamma rays or positrons, which are detected by specialized imaging devices.

The market for nuclear medicine is driven by several factors. One of the key drivers is the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. These diseases require accurate and early diagnosis for effective treatment, and nuclear medicine techniques offer precise imaging capabilities for disease detection, staging, and monitoring.

In conclusion, the global market for nuclear medicine is expanding rapidly due to the increasing prevalence of chronic diseases, technological advancements, supportive government initiatives, and research and development efforts. As the demand for accurate diagnostic tools and personalized treatment options continues to rise, the nuclear medicine market is expected to experience sustained growth in the coming years.

Nuclear Medicine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • GE HealthCare
  • Bayer AG
  • Lantheus
  • Cardinal Health, Inc
  • Bracco
  • Curium
  • Advanced Accelerator Applications (A Novartis Company)
  • Nordion (Canada) Inc
  • Northstar Medical Radioisotopes
  • Isotopia Molecular Imaging Limited
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Nuclear Medicine Market Overview
3.1 Global Nuclear Medicine Market Historical Value (2016-2022)
3.2 Global Nuclear Medicine Market Forecast Value (2023-2031)
4 Global Nuclear Medicine Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Nuclear Medicine Market Segmentation
5.1 Global Nuclear Medicine Market by Type
5.1.1 Market Overview
5.1.2 Diagnostic Nuclear Medicine SPECT (Single-Photon Emission Computed Tomography) PET (Positron Emission Tomography) Radiopharmaceuticals
5.1.3 Therapeutic Nuclear Medicine Beta Emitters Alpha Emitters Brachytherapy Isotopes
5.2 Global Nuclear Medicine Market by Application
5.2.1 Market Overview
5.2.2 Oncology
5.2.3 Cardiology
5.2.4 Neurology
5.2.5 Others
5.3 Global Nuclear Medicine Market by End User
5.3.1 Market Overview
5.3.2 Hospitals and Clinics
5.3.3 Diagnostic Centres
5.3.4 Academic Research Institutions
5.3.5 Others
5.4 Global Nuclear Medicine Market by Region
5.4.1 Market Overview
5.4.2 North America
5.4.3 Europe
5.4.4 Asia Pacific
5.4.5 Latin America
5.4.6 Middle East and Africa
6 North America Nuclear Medicine Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Nuclear Medicine Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Nuclear Medicine Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.6 Australia
8.7 Others
9 Latin America Nuclear Medicine Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Nuclear Medicine Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.5 Others
16 Supplier Landscape
16.1 GE HealthCare
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.1.5 Certifications
16.2 Bayer AG
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Lantheus
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Cardinal Health, Inc.
16.4.1 Financial Analysis
16.4.2 Financial Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Bracco
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Curium
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Advanced Accelerator Applications (A Novartis Company)
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Nordion (Canada) Inc.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Northstar Medical Radioisotopes
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Isotopia Molecular Imaging Limited
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
17 Global Nuclear Medicine Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • GE HealthCare
  • Bayer AG
  • Lantheus
  • Cardinal Health, Inc.
  • Bracco
  • Curium
  • Advanced Accelerator Applications (A Novartis Company)
  • Nordion (Canada) Inc.
  • Northstar Medical Radioisotopes
  • Isotopia Molecular Imaging Limited



Table Information